In late 2025, President Trump signed an Executive Order to expedite the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act.

If finalized, the reclassification would mark a significant policy shift with concrete legal, economic, and research implications. What does this mean for recreational/medical use, state and federal drug law, and cannabis research?

Our panel of experts bring multidisciplinary perspectives to this complicated issue.